ArticleScientific reports2026
Curcumin and ferulic acid activate PPARγ-PGC1α signaling and improve mitochondrial function in a 6-OHDA-induced Parkinson's cellular model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson’s disease (PD) involves mitochondrial dysfunction and oxidative stress. Curcumin (CUR) and ferulic acid (FA) are phenolic compounds with neuroprotective effects, but their roles in improving mitochondrial function in PD remain poorly understood. This study explores the neuroprotective effects of FA and CUR on mitochondrial function via peroxisome proliferator-activated receptor gamma (PPARγ)-peroxisome proliferator-activated receptor gamma co-activator-1 alpha (PGC1α) signaling in SHSY5Y cells exposed to 6-hydroxydopamine (6-OHDA). A PD model was created using 6-OHDA (100 µM) in SH-SY5Y cells. Cells were pretreated with CUR (10 µM) or FA (200 µM) for 24 h, then exposed to 6-OHDA for another 24 h. Cell viability was measured using the MTT assay; apoptosis/necrosis was evaluated with acridine orange-ethidium bromide (AO-EB) staining; oxidative stress was assessed using reactive oxygen species (ROS), malondialdehyde (MDA), and glutathione (GSH) assays; and RT-qPCR analyzed PPARγ and PGC1α mRNA expression. CUR and FA improved cell viability, lowered ROS levels, decreased MDA levels, preserved GSH levels, reduced apoptosis and necrosis, and increased PPARγ and PGC1α mRNA expression compared with 6-OHDA alone. These findings suggest that CUR and FA activate the PPARγ–PGC1α signaling pathway, a key regulator of mitochondrial biogenesis, and are associated with reduced oxidative stress and cell death, highlighting their potential as a therapeutic approach for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.